New technology appraisal guidance published on biologic treatments for RA

Injection

The NICE guidance covers adalimumab, etanercept, infliximab, and abatacept for moderate rheumatoid arthritis after conventional disease-modifying anti-rheumatic drugs have failed

Please register to continue reading this content

Guidelines is completely free for all UK-based healthcare professionals